Homozygous deletion of SMAD4 in breast cancer cell lines and invasive ductal carcinomas

Cancer Biology and Therapy

Volumn 5, Issue 6, 2006, Pages 601-607

  Zhong, Diansheng ^a   Morikawa, Aki ^a,b   Guo, Lizheng ^a   Colpaert, Cecile ^c   Xiong, Li ^a   Nassar, Aziza ^d   Chen, Ceshi ^a   Lamb, Neil ^d   Dong, Jin Tang ^a   Zhou, Wei ^a,d  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Counting alleles; Homozygous deletion; Infiltrative ductal carcinoma; Laser capture microdissection; Signaling; TGF

Indexed keywords

SMAD4 PROTEIN;

ALLELIC IMBALANCE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DNA DETERMINATION; DNA TEMPLATE; GENE DELETION; GENETIC MARKER; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LASER CAPTURE MICRODISSECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 33745778678     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.6.2660     Document Type: Article

References (32)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
2. Callahan R, Cropp C, Merlo GR, Diella F, Venesio T, Lidereau R, Cappa AP, Lisicia DS. Genetic and molecular heterogeneity of breast cancer cells. Clin Chim Acta 1993; 217:63-73.
3. Lagna G, Hata A, Hemmati-Brivanlou A, Massague J. Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways. Nature 1996; 383:832-6.
4. Nakao A, Imamura T, Souchelnytskyi S, Kawabata M, Ishisaki A, Oeda E, Tamaki K, Hanai J, Heldin CH, Miyazono K, ten Dijke P. TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J 1997; 16:5353-62.
5. Chen Y, Bhushan A, Vale W. Smad8 mediates the signaling of the ALK-2 [corrected] receptor serine kinase. Proc Natl Acad Sci USA 1997; 94:12938-43.
6. Nishimura R, Kato Y, Chen D, Harris SE, Mundy GR, Yoneda T. Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic differentiation of the pluripotent mesenchymal precursor cell line C2C12. J Biol Chem 1998; 273:1872-9.
7. Moskaluk CA, Kern SE. Cancer gets Mad: DPC4 and other TGFbeta pathway genes in human cancer. Biochim Biophys Acta 1996; 1288:M31-3.
8. Miyaki M, Kuroki T. Role of Smad4 (DPC4) inactivation in human cancer. Biochem Biophys Res Commun 2003; 306:799-804.
9. Wakefield LM, Piek E, Bottinger EP. TGF-beta signaling in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 2001; 6:67-82.
10. Bottinger EP, Jakubczak JL, Haines DC, Bagnall K, Wakefield LM. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene. Cancer Res 1997; 57:5564-70.
11. Gobbi H, Dupont WD, Simpson JF, Plummer Jr WD, Schuyler PA, Olson SJ, Arteaga CL, Page DL. Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia. J Natl Cancer Inst 1999; 91:2096-101.
12. Gobbi H, Arteaga CL, Jensen RA, Simpson JF, Dupont WD, Olson SJ, Schuyler PA, Plummer Jr WD, Page DL. Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in-situ and invasive carcinomas. Histopathology 2000; 36:168-77.
13. Fynan TM, Reiss M. Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit Rev Oncog 1993; 4:493-540.
14. Sun L, Wu G, Willson JK, Zborowska E, Yang J, Rajkarunanayake I, Wang J, Gentry LE, Wang XF, Brattain MG. Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem 1994; 269:26449-55.
15. Iacobuzio-Donahue CA, Song J, Parmiagiani G, Yeo CJ, Hruban RH, Kern SE. Missense mutations of MADH4: Characterization of the mutational hot spot and functional consequences in human tumors. Clin Cancer Res 2004; 10:1597-604.
16. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, Bova GS, Isaacs WB, Cairns P, Nawroz H, Sidransky D, Casero Jr RA, Meltzer PS, Hahn SA, Kern SE. DPC4 gene in various tumor types. Cancer Res 1996; 56:2527-30.
17. Yokota T, Matsumoto S, Yoshimoto M, Kasumi F, Akiyama F, Sakamoto G, Nakamura Y, Emi M. Mapping of a breast cancer tumor suppressor gene locus to a 4-cM interval on chromosome 18q21. Jpn J Cancer Res 1997; 88:959-64.
18. Zhou W, Galizia G, Lieto E, Goodman SN, Romans KE, Kinzler KW, Vogelstein B, Choti MA, Montgomery EA. Counting alleles reveals a connection between chromosome 18q loss and vascular invasion. Nat Biotechnol 2001; 19:78-81.
19. Chen C, Bhalala HV, Qiao H, Dong JT. A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer. Oncogene 2002; 21:6567-72.
20. Colpaert C, Vermeulen P, Jeuris W, van Beest P, Goovaerts G, Weyler J, Van Dam P, Dirix L, Van Marck E. Early distant relapse in 'node-negative' breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumor. J Pathol 2001; 193:442-9.
21. Zhou W, Goodman M, Lyles R, Lim S, Williams T, Rusthoven K, Mandel J, Amin M, JA. P surgical margin and gleason score as predictors of post-operative recurrence in prostate cancer with or without chromosome 8p allelic imbalance. The Prostate 2004, (in press).
22. Goldberg EK, Glendening JM, Karanjawala Z, Sridhar A, Walker GJ, Hayward NK, Rice AJ, Kurera D, Tebha Y, Fountain JW. Localization of multiple melanoma tumor-suppressor genes on chromosome 11 by use of homozygosity mapping-of-deletions analysis. Am J Hum Genet 2000; 67:417-31.
23. Zhou W, Williams T, Colpaert C, Morikawa A, Zhong D. Digital PCR analysis of allelic status in clinical specimens. In: Demidov VV, Broude NE, eds. DNA Amplification: Current technologies and applications. Norfolk: Horizon Bioscience, 2004:335.
24. Morikawa A, Williams TY, Dirix L, Colpaert C, Goodman M, Lyles RH, Zhong D, Zhou W. Allelic imbalances of chromosome 8p and 18q and their roles in distant relapse of early stage, node-negative breast cancer. Breast Cancer Res 2005; 7:R1051-R7.
25. Shen CY, Yu JC, Lo YL, Kuo CH, Yue CT, Jou YS, Huang CS, Lung JC, Wu CW. Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: An implication for mutator phenotype and breast cancer pathogenesis. Cancer Res 2000; 60:3884-92.
26. Shih IM, Zhou W, Goodman SN, Lengauer C, Kinzler KW, Vogelstein B. Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis. Cancer Res 2001; 61:818-22.
27. Xie W, Mertens JC, Reiss DJ, Rimm DL, Camp RL, Haffty BG, Reiss M. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: A tissue microarray study. Cancer Res 2002; 62:497-505.
28. Stuelten CH, Buck MB, Dippon J, Roberts AB, Fritz P, Knabbe C. Smad4-expression is decreased in breast cancer tissues: A retrospective study. BMC Cancer 2006; 6:25.
29. Jakob J, Nagase S, Gazdar A, Chien M, Morozova I, Russo JJ, Nandula SV, Murty VV, Li CM, Tycko B, Parsons R. Two somatic biallelic lesions within and near SMAD4 in a human breast cancer cell line. Genes Chromosomes Cancer 2005; 42:372-83.
30. Wakefield LM, Yang YA, Dukhanina O. Transforming growth factor-beta and breast cancer: Lessons learned from genetically altered mouse models. Breast Cancer Res 2000; 2:100-6.
31. de Caestecker MP, Piek E, Roberts AB. Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst 2000; 92:1388-402.
32. Chen T, Carter D, Garrigue-Antar L, Reiss M. Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer. Cancer Res 1998; 58:4805-10.